People · Operator
Named in public records as an officer, director or promoter · active 2010–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NexImmune, Inc. | — | Biotechnology | Series B | $35.0M | $308.3M | 2014 |
| Acylin Therapeutics, Inc. | — | Biotechnology | Seed | $4.0M | $88.8M | 2010 |
| Oncofactor Corp | — | Biotechnology | Seed | $3.1M | $44.4M | 2011 |
Janis Naeve at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Janis Naeve on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thong Le | 2 | 12 |
| Chad Waite | 2 | 11 |
| Carl Weissman | 2 | 8 |
| Lindsay Rayle | 2 | 7 |
| Lee Babiss | 2 | 5 |
| Steven Gillis | 1 | 23 |
| Steve Gillis | 1 | 13 |
| Robert Spiegel | 1 | 8 |
| David Schubert | 1 | 6 |
| James Barrett | 1 | 6 |
| Kenneth Carter | 1 | 6 |
| Tony Yao | 1 | 3 |
| David McElligott | 1 | 2 |
| Alain Cappeluti | 1 | 2 |
| Alan Roemer | 1 | 2 |
| Timothy Bertram | 1 | 2 |
| Steven Gills | 1 | 1 |
| Peter DiStefano | 1 | 1 |
| Jonathan Schneck | 1 | 1 |
| Slain Cappeluti | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.